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Synthetic biology enablesmetabolic engineering of industrial microbes to synthesize value-
added molecules. In this, a major challenge is the efﬁcient redirection of carbon to the
desired metabolic pathways. Pinpointing strategies toward this goal requires an in-depth
investigation of the metabolic landscape of the organism, particularly primary metabolism,
to identify precursor and cofactor availability for the target compound. The potent
antimalarial therapeutic artemisinin and its precursors are promising candidate molecules
for production in microbial hosts. Recent advances have demonstrated the production of
artemisinin precursors in engineered yeast strains as an alternative to extraction from
plants. We report the application of in silico and in vivo metabolic pathway analyses
to identify metabolic engineering targets to improve the yield of the direct artemisinin
precursor dihydroartemisinic acid (DHA) in yeast. First, in silico extreme pathway (ExPa)
analysis identiﬁed NADPH-malic enzyme and the oxidative pentose phosphate pathway
(PPP) as mechanisms to meet NADPH demand for DHA synthesis. Next, we compared
key DHA-synthesizing ExPas to the metabolic ﬂux distributions obtained from in vivo
13C metabolic ﬂux analysis of a DHA-synthesizing strain. This comparison revealed that
knocking out ethanol synthesis and overexpressing glucose-6-phosphate dehydrogenase
in the oxidative PPP (gene YNL241C ) or the NADPH-malic enzyme ME2 (YKL029C ) are
vital steps toward overproducing DHA. Finally, we employed in silico ﬂux balance analysis
and minimization of metabolic adjustment on a yeast genome-scale model to identify gene
knockouts for improving DHA yields.The best strategy involved knockout of an oxaloacetate
transporter (YKL120W) and an aspartate aminotransferase (YKL106W), and was predicted
to improve DHA yields by 70-fold. Collectively, our work elucidates multiple non-trivial
metabolic engineering strategies for improving DHA yield in yeast.
Keywords: artemisinin, metabolic engineering, metabolic pathway, extreme pathway, isotope labeling, metabolic
flux analysis, flux balance analysis, minimization of metabolic adjustment
INTRODUCTION
Artemisinin-based combination therapy (ACT) is currently the
most commonly used treatment for malaria (Weathers et al., 2006;
Eastman and Fidock, 2009; Price and Douglas, 2009), an infec-
tious disease that is widespread particularly in regions of Africa,
Asia, and South America (Feachem et al., 2010; O’Meara et al.,
2010). Artemisinin, the primary component of ACT, is a natu-
rally produced sesquiterpene lactone endoperoxide. Artemisinin
and its derivatives have also been found to exhibit anti-cancer
properties (Ferreira et al., 2010) such as inducing apoptosis in
lung cancer cells (Gao et al., 2013) and preventing cell prolifer-
ation in breast cancer cells (Ba et al., 2012; Zhang et al., 2013).
In nature, artemisinin is synthesized by the plant Artemisia
annua through conversion of the intermediate sesquiterpene far-
nesyl pyrophosphate (FPP; Bertea et al., 2005; Liu et al., 2011).
The precursor FPP is synthesized from the primary metabolite
acetyl-coenzyme A (CoA) via the mevalonate (MVA) pathway,
or from glyceraldehyde-3-phosphate (GAP) and pyruvate via the
methylerythritol phosphate (MEP) pathway (Figure 1). A. annua
has been the primary source for meeting almost all the world-
wide demand for artemisinin, despite producing artemisinin up
to less than 1.0–1.5% of its dry weight (Kindermans et al., 2007;
Covello, 2008). Not surprisingly, the price of artemisinin has var-
ied substantially from a lower bound of US$150–170 kg−1 to an
upper bound of US$1,100–1,500 kg−1 (World Health Organiza-
tion, 2010), partially due to variability in the cultivation of A.
annua. Therefore, it is necessary to explore avenues for reliable
production of artemisinin that offer this drug at the minimal pos-
sible cost to developing countries (Covello, 2008). To achieve this
goal, researchers have demonstrated the synthesis of artemisinin
precursors in microbes (Ro et al., 2006; Zhang et al., 2008; West-
fall et al., 2012; Paddon et al., 2013) or plants (e.g., Zhang et al.,
2011) engineered to express genes from the A. annua artemisinin
pathway, thereby enabling conversion of endogenously produced
FPP to artemisinin precursors. Orthogonally, chemical synthe-
ses for artemisinin from starting materials ranging from natural
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FIGURE 1 | Artemisinin precursor synthesis pathways in yeast. In the
native isoprenoid biosynthesis pathway in yeast (A), IPP synthesized via the
MVA pathway is converted to FPP. HMGR is a key enzyme in the isoprenoid
biosynthetic pathway that feeds the artemisinin precursor synthesis pathway
(B). Steps that are not known to be catalyzed by enzymes are depicted with
dashed lines. Enzyme and metabolite name abbreviations: AaDBR2, A. annua
double bond reductase; ADH, (dihydroartemisinic) aldehyde dehydrogenase;
ADS, amorpha-4,11-diene synthase; CYP71AV1, cytochrome P450
monooxygenase; CPR, A. annua cytochrome P450 reductase; CoA,
coenzyme A; DMAPP, dimethylallyl diphosphate; FDS, farnesyl
diphosphate synthase; FPP, farnesyl pyrophosphate; HMG-CoA,
3-hydroxy-3-methylglutaryl-CoA; HMGR, HMG-CoA reductase; IPA,
isopentenyladenine; IPP, isopentenyl diphosphate; MVA, mevalonate; SQS,
squalene synthase. Adapted from Zhang et al. (2008) andTeoh et al. (2006).
terpenoids (reviewed inCovello,2008) to cyclohexenone (e.g., Zhu
and Cook, 2012) have been reported.
The ﬁrst applications of synthetic biology to artemisinin pro-
duction were those of Keasling and colleagues (Ro et al., 2006)
and of Covello and colleagues (Teoh et al., 2006). Both groups
reported the engineering of Saccharomyces cerevisiae to produce
artemisinic acid (AA), which can be converted to artemisinin
through a sequence of chemical steps. The breakthrough work
by Keasling and colleagues was followed by several reports of sig-
niﬁcantly improved AA titers from the same group (Westfall et al.,
2012; Paddon et al., 2013; see detailed description below). Inde-
pendently, Covello and colleagues demonstrated the production of
dihydroartemisinic acid (DHA) in S. cerevisiae (Zhang et al., 2008).
As an artemisinin precursor, DHA is preferable to AA for multiple
reasons. Firstly, DHA can be oxidized to artemisinin sponta-
neously without the involvement of enzymes (Sy and Brown, 2002;
Brown and Sy, 2004). In planta artemisinin biosynthesis is hypoth-
esized to proceed through DHA via this mechanism (Bertea et al.,
2005), circumstantial evidence for which comes from the observa-
tion that DHA-rich chemotypes of A. annua exhibit signiﬁcantly
higher artemisinin production than AA-rich chemotypes (Wal-
laart et al., 2000; Rydén et al., 2010). Secondly, semi-synthetic
routes to artemisinin production have relied upon DHA as the
startingmaterial (e.g., Lévesque andSeeberger,2012;Westfall et al.,
2012). Thus, the possibility of engineering DHA biosynthesis in
microbes opens up an alternative route for artemisinin synthesis
in yeast, which has the potential to be executed completely in vivo
(Zhang et al., 2008).
The AA route for artemisinin production has recently seen
impressive scientiﬁc success and commercialization (Hale et al.,
2007; Chandran et al., 2008; Lenihan et al., 2008; Westfall et al.,
2012; Paddon et al., 2013). The titers and yields of artemisinin or
its precursors have been improved substantially by optimization of
downstream metabolic pathways as well as process development.
The work of Keasling and coworkers improved FPP produc-
tion, and thereby AA titers, in the initial AA-synthesizing strains
(Ro et al., 2006) by ingeniously combining several approaches.
These included (i) overexpression of upc2-1, a transcription factor
involved in the regulation of sterol production, to increase ﬂux
through the MVA pathway; (ii) downregulation of squalene syn-
thase (ERG9), which diverts FPP away from DHA production
to sterol production; and (iii) overexpression of 3-hydroxy-
3-methylglutaryl (HMG)-CoA reductase (HMGR) to enhance
conversion of HMG-CoA to MVA. By employing these strate-
gies in concert, Keasling and colleagues were able to improve
the titer of amorpha-4,11-diene, a precursor of the artemisinin
pathway (Figure 1), by more than 15-fold over the original
AA-synthesizing strain (Ro et al., 2006). Further work (Lenihan
et al., 2008) improved AA titers of these strains through process
optimization of fermentation parameters. Recently, Keasling and
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colleagues employed the strategy of overexpressing all enzymes of
the MVA pathway together with repression of ERG9 to achieve
very high titers and yields of amorpha-4,11-diene and AA (West-
fall et al., 2012). While all previous attempts employed galactose
or glucose as the sole carbon source, Westfall et al. (2012)
fed ethanol as a second carbon source and obtained yields of
amorpha-4,11-diene higher than 18 C mol % (Figure 2). More
recently, Paddon et al. (2013) improved AA titers by more than
15-fold to 25 g L−1. Coupled with their development of a scal-
able chemical process for conversion of AA to artemisinin, this
work is a major breakthrough in the commercial production of
artemisinin.
The approaches described above have improved AA yields
almost exclusively by manipulating ﬂux through downstream
pathways, speciﬁcally the MVA and sterol biosynthesis pathways.
However, another powerful approach to enhance the production
of artemisinin precursors would be to engineer upstream (pri-
mary and central carbon) metabolism. Several computational
and experimental tools such as extreme pathway (ExPa) analysis
(Wiback and Palsson, 2002; Llaneras and Picó, 2010), ﬂux bal-
ance analysis (FBA; Orth et al., 2010), minimization of metabolic
FIGURE 2 | Calculated (red bars) and previously reported (blue bars)
yields of artemisinin precursors.The theoretical maximum yield of the
artemisinin precursors amorpha-4,11-diene, AA, or DHA is 22 mol/100 mol
glucose (Glc) (left axis) or 55 C mol % (right axis). One ExPa (ExPa C, with
ME2 active), yields 18 mol DHA/100 mol glucose), with concomitant
biomass production (3 mol/100 mol glucose). Here, ME2 supplies reductant
to meet the NADPH requirement. Another ExPa (ExPa D, with an active
oxidative PPP), yields 11 mol DHA/100 mol glucose, with concomitant
biomass production (6 mol/100 mol glucose). Here, the oxidative PPP
supplies reductant to meet the NADPH requirement. Figure 3 depicts ﬂux
distributions through these ExPas. The yields of artemisinin precursors in
the pioneering microbial production studies (Ro et al., 2006; Zhang et al.,
2011) were relatively low; however, subsequent work obtained further
improvement in amorpha-4,11-diene and AA yield by increasing ﬂux through
the MVA pathway and varying feed composition. Recently, Westfall et al.
(2012) achieved drastic improvement in amorpha-4,11-diene yield of close to
20 C mol % by using an optimized yeast strain with a mixed feed consisting
of ethanol (EtOH) and Glc. They achieved yields of 1.1 C mol % with
glucose as carbon source, which increased to 3.2 C mol % by using
KH2PO4 with the glucose feed, to 6.0 C mol % by using glucose and EtOH
mixed feed. The highest yields obtained were 17.0 and 18.7 C mol % with a
restricted EtOH feed.
adjustment (MOMA) analysis (Segrè et al., 2002) as well as 13C
metabolic ﬂux analysis (13C MFA; e.g., Feng et al., 2010; Papini
et al., 2012; Ahn and Antoniewicz, 2013; Nargund and Sriram,
2013) are now available to dissect metabolism, derive insight
and propose metabolic engineering strategies. Because primary
metabolic pathways supply substantial amounts of carbon and
reductant to downstream pathways such as MVA and sesquiter-
pene synthesis, such strategies may identify non-trivial metabolic
engineering strategies and thus play a very signiﬁcant role in
improving ﬂux to AA or DHA. There have been relatively few
reports of computationally inferred genetic engineering strate-
gies in upstream metabolism for improving microbial yields of
intermediary or secondary metabolites. Studies that have success-
fully accomplished this include those focusing on the production
of L-valine (Park et al., 2007), lycopene (Alper et al., 2005), and
C14–C16 fatty acids (Ranganathan et al., 2012) by Escherichia
coli. In one study directed at secondary metabolite production
by yeast, Asadollahi et al. (2009) identiﬁed genetic interventions
toward increased production of sesquiterpenes synthesized via the
MVA pathway, by in silico analyses of a genome-scale model of
yeast metabolism. They predicted that knocking out glutamate
dehydrogenase (GDH1), whose product assimilates nitrogen at
the expense of NADPH, will result in a 10-fold increase in the
production of the sesquiterpene cubebol. Mechanistically, this
knockout was predicted to shunt carbon via an alternative reac-
tion that consumes NADH instead of NADPH, thus improving
NADPH availability to the MVA pathway and sesquiterpene syn-
thesis. Indeed, on in vivo implementation, the GDH1 knockout
strategy led to a signiﬁcant (∼twofold) increase in the titer of
cubebol.
Because modeling approaches are immensely useful in syn-
thetic biology (Zheng and Sriram, 2010), this article investi-
gates strategies for improving DHA yields in engineered yeast
by employing a variety of computation-assisted methodologies.
These include ExPa analysis, 13C MFA, FBA, and MOMA analysis.
ExPa and elementary ﬂux mode analysis enable detailed inves-
tigation of the ﬂux distribution space (phenotypic space) of a
metabolic network (Schilling et al., 2000) to obtain insights on the
network’s capabilities and limitations. Such analyses can suggest
genetic intervention strategies to effect a desired outcome from the
network Becker et al. (2011). 13C MFA is a powerful methodology
currently used for estimating intracellular ﬂuxes. In this method-
ology, isotope labeling signatures obtained from feeding a mixture
of 13C and 12C carbon sources to an organism, in conjunctionwith
extracellular ﬂux measurements, are used to evaluate intracellular
ﬂux distributions (e.g., Wiechert, 2001; Sriram et al., 2004, 2008;
Murphy et al., 2013). FBA,a complementary approach to 13CMFA,
optimizes a metabolic objective to estimate or predict ﬂux distri-
bution seven at the genome-scale (Grafahrend-Belau et al., 2009;
Orth et al., 2010). In genome-scale FBA, an organism’s inven-
tory of metabolic reactions is used to assemble a stoichiometric
matrix. Thermodynamic irreversibility constraints as well as mea-
surements of a few extracellular ﬂuxes such as substrate uptake
and product secretion are used to constrain the null space of this
matrix, thus generating a phenotypic space of feasible ﬂux distri-
butions. An objective function such as maximization of biomass
production is then employed to isolate a particular solutionwithin
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the feasible solution space. Several extensions of the FBA approach
enable prediction of changes in ﬂux distributions due to genetic
interventions, including OptKnock (Burgard et al., 2003), Opt-
Strain (Pharkya et al., 2004), OptForce (Ranganathan et al., 2010),
and MOMA (Segrè et al., 2002). MOMA predicts ﬂux alterations
resulting from gene knockouts, and thereby enables identiﬁcation
of advantageous knockouts. It is based on the premise that gene
knockouts restrict the wild type phenotypic space of an organ-
ism, and that organisms respond by minimally adjusting their
wild type ﬂux distribution to make it lie within the restricted
phenotypic space (Segrè et al., 2002). This contrasts with FBA,
which assumes that organisms respond by ﬁnding a new opti-
mum of their objective function within the restricted phenotypic
space.
To our knowledge, this is the ﬁrst study utilizing a variety of
computational and experimental pathway analysis techniques to
identify metabolic engineering targets for enhanced production of
artemisinin precursors in yeast. Together, our analyses elucidate
upstream bottlenecks in DHA synthesis and suggest non-trivial
genetic intervention strategies for pushing carbon toward theDHA
pathway and thereby improving DHA yield.
MATERIALS AND METHODS
ExPa ANALYSIS
For ExPa analysis, we constructed a metabolic model of yeast engi-
neered to synthesize DHA. This model consisted of central carbon
metabolic pathways native to yeast including glycolysis, pentose
phosphate pathway (PPP), tricarboxylic acid (TCA) cycle, MVA
pathway, pathways for synthesis of biomass components and a con-
solidated reaction encompassing the pathway from MVA to DHA.
Altogether, this model contained 63 reactions and 51 metabolites.
TodetermineExPas,we analyzed thismodelwith the expa program
from Bell and Palsson (2004). The resulting ExPas are tabulated in
Data Sheet 1 in Supplementary Material.
CELL CULTURE, STRAIN CHARACTERIZATION, AND METABOLIC
MEASUREMENTS
Yeast cell culture in microplates
We used three S. cerevisiae strains in this study (FyAA, FyDHA,
and Fy0; Zhang et al., 2008), all of which were designer yeast
strains carrying lysine and methionine auxotrophies. Strain FyAA
was engineered with genes for the synthesis of AA, speciﬁcally A.
annua farnesyl diphosphate synthase (FDS), amorpha-4,11-diene
synthase (ADS), cytochrome P450 monooxygenase (CYP71AV1),
and A. annua cytochrome P450 reductase (CPR). Strain FyDHA
was engineered with genes for the synthesis of DHA, speciﬁ-
cally FDS, ADS, CYP71AV1, CPR, and A. annua double bond
reductase (AaDBR2). Figure 1 depicts the reactions catalyzed
by the products of these genes. Strain Fy0 was an empty vec-
tor control. Further genetic engineering details are provided in
the supplementary material of Zhang et al. (2008). We grew the
strains in synthetic deﬁned base yeast minimal medium (Clon-
tech Laboratories, Mountain View, CA, USA) supplemented with
trace amounts of lysine and methionine due to the auxotro-
phies in the strains. This medium was supplemented with 2%
(w/v) glucose or galactose as carbon source. All growth and 13C
MFA experiments were performed on 2 mL batch cultures in
deep-well microplates in a Biotek Synergy HT microplate reader
(Biotek Instruments, Winooski, VT, USA) at 30◦C with contin-
uous shaking. To induce DHA or AA production, cultures grew
for 45–55 h on this medium supplemented with 2% (w/v) galac-
tose as the carbon source. For isotope labeling studies, we used
either 20% U-13C galactose or 100% 1-13C galactose in parallel
labeling experiments. To harvest cells we centrifuged the cell sus-
pensions, separated the supernatant and immediately froze the
pellets in liquid nitrogen to arrest metabolism. The pellets and
supernatants were lyophilized and stored at −80◦C until further
analysis.
Strain characterization
Expression of recombinant genes in the engineered strains was
conﬁrmed by RT-PCR, using primers from Zhang et al. (2008).
A. annua actin1 was used as a negative control, whereas the yeast
ACT1 andTAF10 were used as positive controls (Teste et al., 2009).
Primers (sequences are listed in Data Sheet 2 in Supplemen-
tary Material) were obtained from Integrated DNA Technologies
(Coralville, IA, USA).
Cell growth rates were determined via online optical density
measurements on the Biotek microplate reader. Measurements
for glucose, ethanol, and glycerol were performed by analyzing
the supernatant with a YSI 2700 Select metabolite analyzer (YSI
Life Sciences, Yellow Springs, OH, USA), using a measurement kit
appropriate for each metabolite. These measurements are listed
in Data Sheet 2 in Supplementary Material. AA and DHA were
extracted by using protocols adapted from Zhang et al. (2008)
and quantiﬁed by gas-chromatography-mass spectrometry (GC-
MS) of their TMS derivatives, using methyl stearate as an internal
standard.
Extraction and analysis of proteinogenic amino acids for 13C
isotopomer measurements
Proteinogenic aminoacids in cell pelletswere obtainedby vacuum-
hydrolyzing the pellets with 6N hydrochloric acid (Thermo
Scientiﬁc, Rockford, IL, USA). The hydrolysate was mixed
with a known amount of norleucine as an internal standard
and derivatized by adding 100 μL N-(tert-butyldimethylsilyl)-
N-methyltriﬂuoroacetamide (MTBSTFA; Thermo Scientiﬁc) in
100 μL dimethylformamide (Thermo Scientiﬁc) and heating at
70◦C for 1 h. GC-MS analysis of 1 μL of this derivatized mixture
was performed using previously published instrument methods
(Sriram et al., 2008) on a Varian 300MS quadrupole GC-MS unit
(Bruker, Billerica, MA, USA) equipped with a VF5-ms column of
dimensions 0.25 mm × 30 m × 0.25 μm and capable of detecting
ions by electron ionization. Quantiﬁcation of amino acids in the
biomass was performed by comparing the chromatographic peak
of each amino acid with that of the norleucine internal standard.
Isotopomer abundances obtained from the mass spectrum of each
amino acid were processed to ﬁlter out natural abundances of ele-
ments other than metabolic carbon, using a previously developed
in-house MATLAB program, whose accuracy has been veriﬁed by
using amino acid isotopomer mixtures of known isotopomeric
composition (Sriram et al., 2008). Isotopomer abundances for
the three strains are reported in Data Sheet 2 in Supplementary
Material.
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Reproducibility and statistics
All experiments were performedwith two or three biological repli-
cates, and statistical signiﬁcance was determined by calculating
p-values through a Student’s t-test.
Evaluation of metabolic ﬂuxes from 13C isotopomer data
We evaluated ﬂuxes from the 13C mass isotopomer data and extra-
cellular ﬂux measurements by using our ﬂux evaluation program
NMR2Flux+ (Sriram et al., 2004, 2008) to ﬁt this data to a steady
state ﬂux-isotopomer model. This model consisted of yeast cen-
tral carbon metabolic pathways, including glycolysis, PPP, TCA
cycle, and anaplerotic pathways. For the retrobiosynthetic recon-
struction of metabolic precursor mass isotopomer distributions
(MIDs) from the amino acid MIDs (e.g., pyruvate from alanine or
oxaloacetate from aspartic acid), we used standard pathways from
the precursors to the amino acids (Szyperski, 1995, 1998). These
pathways are universally conserved across life (Romano and Con-
way,1996).Weused standardmodels for the biosynthesis of amino
acids from the intermediates of these pathways (e.g., Szyperski,
1995). We found that labeling of the proteinogenic amino acids
except methionine and lysine was very close to 20% for cells grown
on 20% U-13C galactose, which indicates attainment of isotopic
steady state (data not shown). However, the metabolism is still at
pseudo-steady state due to the batch culture. Statistical analysis
was performed by the NMR2Flux+ program, using a bootstrap
Monte Carlo simulation to execute 100 runs of the ﬂux evaluation
by perturbing measurements by their known standard error, as
previously described (Sriram et al., 2004, 2008). Evaluated ﬂuxes
for the three strains are reported in Data Sheet 2 in Supplementary
Material.
FBA AND MOMA ANALYSIS
We modiﬁed the iMM904 genome-scale model for S. cerevisiae
(Mo et al., 2009) by appending it with the reactions necessary to
synthesize DHA from FPP. We constrained this model with the
measured extracellular uptake ﬂuxes (glucose or galactose) as well
as intracellular ﬂuxes estimated from the 13C isotopomer data.
The open-source COBRA toolbox (Schellenberger et al., 2011)
was used to perform FBA and MOMA analysis on the model.
For FBA, we used maximization of biomass growth as the objec-
tive function. We performed MOMA to assess the effects of all
possible single-gene knockouts on DHA production. For this, we
used an in-house MATLAB script (available on request) to auto-
mate certain repetitive steps such as recurring calls to COBRA.
The non-lethal single-gene knockouts that signiﬁcantly increased
DHA yields were used in a second iteration of the MOMA analysis
to identify double-gene knockouts that enhanced DHA produc-
tion. The results of this analysis are available in Data Sheet 3 in
Supplementary Material.
RESULTS AND DISCUSSION
The currently available synthesis routes for DHA (or AA) use
galactose or glucose as carbon sources (Ro et al., 2006; Teoh et al.,
2006; Zhang et al., 2008; Paddon et al., 2013). Strategizing how
to produce DHA from these substrates at high yield is a complex
problem, solving which requires answering the following ques-
tions. (i)What is the theoretical maximal yield of DHA on glucose
or galactose? (ii) Is this yield limited by the availability of reduc-
tant cofactors? (iii) Which conﬁguration of pathways and ﬂuxes
favors a high yield? (iv) Do current DHA-synthesizing strains
operate near or distantly from such a conﬁguration? (v) Which
minimal sets of genetic interventions can drastically improve the
yield of a low DHA-producing strain? Below, we describe our
computational analyses (ExPa analysis and MOMA analysis) and
experimental investigations (13C MFA) toward answering these
questions.
THEORETICAL MAXIMAL YIELD OF DHA OR AA ON GLUCOSE
The value of the maximal yield of DHA on glucose (or a sim-
ilar sugar such as galactose) depends on whether the reductant
cofactors NADH and NADPH are considered in the analysis, and
whether a distinction is made between the cofactors NADH and
NADPH. A cofactor-free theoretical yield calculation reveals that
yeast can produce a maximum yield of 22 mol DHA/100 mol glu-
cose, or 1 mol DHA per 4.5 mol glucose (Figure 2). Metabolically,
this would proceed as follows. Glycolysis would convert 4.5 mol
glucose to 9 mol acetyl-CoA, which the MVA pathway would
condense to form 3 mol dimethylallyl diphosphate (DMAPP).
DMAPP would further condense to form FPP in a molar pro-
portion of 3 DMAPP:1 FPP. FPP would then be converted to
amorphadiene and ultimately to DHA in a 1:1 molar proportion
(Bertea et al., 2005). This DHA yield is equivalent to 55 C mol %,
wherein the 45 C mol % carbon loss is due to the release of CO2 in
multiple pathway steps. This calculation and yield value also apply
to AA production from glucose or galactose.
The fact that artemisinin, DHA and AA are signiﬁcantly
reduced compounds necessitates the consideration of reductant
(cofactor) demand and supply in this yield calculation. In the
upstream section of the pathway described above, the conversion
of 4.5 mol glucose to 9 mol acetyl-CoA supplies 18 mol NADH. In
the downstream section, 6 mol NADPH is required for the con-
version of 9 mol acetyl-CoA to 3 mol DMAPP. Therefore, if no
distinction is made between the NADH and NADPH, this path-
way is self-sufﬁcient in reductant because the demand of 6 mol
NADPH is met by a supply of 18 mol NADH.
The interchangeability of NADH and NADPH invoked in the
above analysis is contingent upon the availability of a transhydro-
genase enzyme that converts NADH to NADPH (Stephanopoulos
et al., 1998). However, there is no evidence for a transhydrogenase
in yeast (Bruinenberg et al., 1983; Nissen et al., 2001). Therefore,
other NADPH-supplying pathways will have to be recruited to
make DHA production feasible. This complicates the theoreti-
cal yield calculation for three reasons. Firstly, multiple pathways
including the oxidative PPP and anaplerotic cycles can supply
NADPH either by themselves or in combination. Secondly some
of these pathways, such as the oxidative PPP, supply NADPH at
the expense of carbon, so that recruiting them for NADPH pro-
vision can compromise the maximal yield of DHA. Thirdly, the
practical necessity of concurrently producing biomass with DHA
will obviously reduce the maximal yield of DHA. To analyze this
complex set of possibilities and delineate all possible pathway con-
ﬁgurations for DHA synthesis with or without cofactor require-
ment, we performed ExPa analysis of the underlying metabolic
network.
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ExPa ANALYSIS OF DHA SYNTHESIS NETWORK
Colloquially, an ExPa represents one way of “walking through a
metabolic network.” Mathematically, ExPas are the edges of the
polyhedral cones that represent the hyperdimensional phenotypic
space that a metabolic network can occupy (Bell and Palsson,
2004; Palsson, 2006). ExPa analysis has previously been applied
to a variety of systems on different scales from small scale net-
works of red blood cells to genome-scale pathway analysis of
the inﬂuenza virus to elucidate important metabolic properties
of the systems (Schilling and Palsson, 2000; Wiback and Palsson,
2002). Amongst the three types of ExPas (types I, II, and III)
classiﬁed by Palsson (2006), we are interested in types I and III.
Type I ExPas effect the conversion of a substrate or substrates
to a product or products along with the transport of the sub-
strates and products across the cell membrane. Type III ExPas
involve intracellular cycles with no transport across the cell mem-
brane. To perform ExPa analysis, we constructed a simpliﬁed (less
than genome-scale)metabolicmodel of yeast capable of producing
bothDHAand biomass (Data Sheet 1 in SupplementaryMaterial).
Thismodel includes 63 reactions including exchange reactions and
51 metabolites including cofactors. We then performed ExPa anal-
ysis on the model by (i) neglecting and (ii) considering cofactor
requirements to gain insights about the capabilities of the network.
Table 1 presents a summary of ExPa families for both cases, and
Figure 3 depicts ﬂux distributions through four selected ExPas.
Of these, ExPa A was obtained from a cofactor-free model, and
ExPas B, C, and D were obtained by considering cofactor require-
ments.
COFACTOR-FREE ExPa ANALYSIS REVEALS IMPORTANT CLASSES OF
PATHWAYS TOWARD DHA SYNTHESIS
Acofactor-free ExPa analysis of a network, although an incomplete
depiction of the network, permits the delineation of major classes
of metabolic routes through it. Such an analysis of the metabolic
model in Data Sheet 1 in Supplementary Material revealed 50 type
I, 6 type II, and 18 type III ExPas (Table 1 and Data Sheet 1 in Sup-
plementary Material). Of these, only ﬁve ExPas synthesized DHA
as their sole product, whereas the rest synthesized various secreted
metabolites (e.g., glycerol, ethanol, and acetate), biomass or a com-
bination of biomass and secreted metabolites. Interestingly, none
of the biomass-producing ExPas concurrently synthesized DHA
(Table 1). The DHA yield in the DHA-synthesizing ExPa A was
equal to the previously calculated theoretical maximum of 22 mol
DHA/100 mol glucose (Figure 3A).
INCLUSION OF COFACTOR REQUIREMENT RECRUITS NADPH-MALIC
ENZYME (ME2) OR THE OXIDATIVE PPP FOR NADPH PROVISION TO
DHA SYNTHESIS PATHWAY
We repeated the foregoing ExPa analysis for a more realistic sce-
nario that considered cofactor requirements and did not include a
Table 1 | Summary of ExPa families for a yeast strain synthesizing DHA from glucose, in the absence and presence of cofactor requirement.
Cofactor-free With cofactor requirement
ExPa familya # of ExPas Maximal yields # of ExPas Maximal yields
DHA productionb 5
(#1 to #5)
DHA: 22 238
(#1 to #238)
DHA: 22
DHA and biomass productionc 0 N/A 94
(#239 to #332)
DHA:
Biomass:
18
10
Biomass production 11
(#6 to #16)
Biomass: 16 383
(#333 to #715)
Biomass: 11
All carbon lost to CO2 10
(#17 to #26)
CO2: 600 108
(#716 to #823)
CO2: 600
Metabolite production via glycolysis 10
(#27 to #36)
Glycerol:
Ethanol:
200
200
83
(#824 to #906)
Glycerol:
Ethanol:
164
200
Metabolite production via PPP 14
(#37 to #50)
Glycerol:
Ethanol:
167
167
161
(#907 to #1067)
Glycerol:
Ethanol:
137
167
Type II ExPas 6
(#51 to #56)
N/A 0 N/A
Type III ExPas 18
(#57 to #74)
N/A 19
(#1068 to #1086)
N/A
ExPa analysis revealed maximal DHA yield of 22 mol/100 mol glucose in both cases. Simultaneous DHA and biomass production was possible only when cofactor
requirements were considered. The numerals following the hashes “#” in the “# of ExPas” columns denote pathway numbers in Data Sheet 1 in Supplementary
Materials. All yields are in mol/100 mol glucose.
aExPas are type I unless otherwise speciﬁed.See Palsson (2006) and text for deﬁnitions of ExPa types.
bNADPH corresponding to maximal DHA yield is supplied by the ME2 reaction; supply of NADPH by the PPP results in lower yields.
cThis is the most important ExPa family, as it provides insights into strategies for improving overall DHA yield.
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FIGURE 3 | Key DHA- or AA-synthesizing ExPas in yeast. Four ExPas that
synthesize DHA (or AA) and/or biomass are shown. Each ExPa is depicted on
a network diagram by highlighting the reactions active in it. The intensities
of green glows around arrows are proportional to the ﬂuxes of the
corresponding reactions; numerals alongside the arrows indicate ﬂux values.
(A) ExPa A, producing the theoretical maximum DHA yield of 22 mol/100 mol
glucose, without considering cofactor requirement or availability. There is no
biomass production and all possible carbon is diverted toward DHA synthesis.
(B) ExPa B, producing the theoretical maximum DHA yield of 22 mol/100 mol
glucose, by accounting for cofactor requirement and availability. There
is no biomass production. Here, the NADPH requirement is met by a
pyruvate  oxaloacetate  malate  pyruvate shuttle via ME2. (C) ExPa C,
producing a high DHA yield of 18 mol/100 mol glucose, with concomitant
biomass production of 3 mol/100 mol glucose. ME2 supplies reductant to
meet the NADPH requirement. (D) ExPa D, producing substantial DHA yield
of 11 mol/100 mol glucose, with concomitant biomass production of
6 mol/100 mol glucose. Here, the oxidative PPP supplies reductant to meet
the NADPH requirement.
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transhydrogenase to interconvert NADH and NADPH. This anal-
ysis resulted in 1086 ExPas with 1067 type I, 0 type II, and 19 type
III ExPas (Table 1 and Data Sheet 1 in Supplementary Material).
Interestingly, the maximal DHA yield obtained from this analysis
was identical to the theoreticalmaximal yield, indicating that some
reactions in the network are able to supply the desired cofactors
without shunting any carbon away from DHA production. For
instance, one ExPa (ExPa B) gave a DHA yield of 22 mol/100 mol
glucose by providing NADPH via ME2 with no concomitant
biomass production (Figure 3B). Here, a pyruvate  oxaloac-
etate  malate  pyruvate shuttle, with the malate  pyruvate
conversion catalyzed by ME2, meets the NADPH requirement of
DHA synthesis. In all the 238 ExPas that exclusively synthesized
DHA, the NADPH requirements were met either by a coupling
of the pyruvate carboxylase and ME2 reactions or by operation
of the oxidative PPP. In fact, the ME2 reaction for converting
malate to pyruvate and the oxidative branch of the PPP are the
only two means of producing NADPH in the network. ExPas
that recruited the oxidative PPP to meet the NADPH requirement
were associated with a DHA yield lower than the theoretical max-
imum, because the oxidative PPP loses signiﬁcant carbon as CO2.
Consequently, ME2 is preferable to the oxidative PPP as a source
of NADPH for DHA synthesis. This makes ME2 an attractive
metabolic engineering target.
Consideration of cofactor requirements resulted in an impor-
tant set of 94 ExPas that simultaneously produced DHA and
biomass (Data Sheet 1 in Supplementary Material and Table 1; see
examples in Figures 3C,D). These pathways are important to our
objective because an overall improvement in DHA yield requires
the production of both DHA and biomass at high yields. How-
ever, concomitant synthesis of DHA and biomass involves many
NADPH-consuming reactions with conﬂictingNADPHdemands.
The NADPH demands of DHA biosynthesis are explained earlier
in this section; biomass synthesis requires NADPH for the con-
version of central carbon metabolic precursors to proteinogenic
amino acids and lipogenic fatty acids. Thus, an increase in DHA
yield is accompanied by a decrease in biomass yield and vice versa.
Two important ExPas that coupled DHA and biomass production
are depicted in Figures 3C,D. ExPa C (Figure 3C) produced a high
DHA yield of 18 mol/100 mol glucose, with concomitant biomass
production of 3 mol/100 mol glucose. ME2 supplied reductant
to meet the NADPH requirement. ExPa D (Figure 3D) produced
substantial DHA yield of 11 mol/100 mol glucose, with concomi-
tant biomass production of 6 mol/100 mol glucose. Here, the
oxidative PPP supplied reductant to meet the NADPH require-
ment. Thus, the ExPa analysis provided insights on the capabilities
of the DHA biosynthesis metabolic network, and identiﬁed ME2
and the oxidative PPP as two critical metabolic engineering
targets.
However, ExPa analysis only identiﬁes the modes of the net-
work, as each ExPa is the edge of the realizable ﬂux cone. Because
a real ﬂux distribution would be a linear combination of a number
of ExPas, it will contain pathways that produce unneeded metabo-
lites. Furthermore, ExPa analysis does not take in to account the
carbon requirement for the de novo synthesis of cofactors and
energy carriers such as ATP. In the absence of these processes
that consume carbon, it overestimates production of biomass
and other metabolites compared to experimental results. As a
result, the actual improvements in yields would be lower than
predicted by the ExPas analysis. To obtain more realistic predic-
tions, we performed ﬂux determination of the DHA-synthesizing
strain experimentally using 13C MFA.
13C MFA AND EXTRACELLULAR MEASUREMENTS OF
DHA-SYNTHESIZING STRAIN REVEAL NEGLIGIBLE PPP AND LOW TCA
CYCLE FLUXES AS WELL AS SUBSTANTIAL FERMENTATIVE FLUXES
We performed comparative 13C MFA of the three yeast strains
Fy0, FyAA, and FyDHA. First, we used RT-PCR to verify that these
strains correctly express the recombinant genes engineered into
them (Figure 4A). We also veriﬁed the strains produce the sec-
ondary metabolites expected of them: FyAA produced AA but not
DHA, FyDHA produced both DHA and AA, whereas Fy0 produced
neither compound (data not shown). Figure 4B depicts transient
DHA production by FyDHA. Extracellular ﬂux measurements on
these strains (Figure 4C) showed that ∼50% of the consumed
galactose was directed toward ethanol, 1% toward glycerol and less
than 10% toward biomass. Thus, despite aerobic conditions, the
strains exhibited substantial fermentative metabolism. Therefore,
an initial strategy for improving DHA yields should be the dele-
tion of the ethanol fermentation pathway, which can be expected
to double the carbon available for DHA and biomass production.
For a more profound understanding of the metabolic behavior
of these strains, we performed 13C MFA on them. Figure 5 depicts
key isotopomer trends that emerged from the 13C labeling exper-
iments. Surprisingly, we did not observe any major signiﬁcant
differences in the amino acid isotopomer abundances between the
three strains (Data Sheet 2 in Supplementary Material). This was
conﬁrmed by a principal component analysis of the isotopomer
abundance data, in which all three strains clustered quite close
together, although the FyAA and FyDHA and strains were slightly
closer to each other than each was to the control strain Fy0 (data
not shown). Figure 6 presents the ﬂux maps obtained from 13C
MFA, using the metabolic model listed in Data Sheet 2 in Supple-
mentary Material. This model did not consider cofactors. NADPH
and other cofactors are often consumed in processes such as scav-
enging reductive oxygen species, making it difﬁcult to estimate
ﬂuxes in real cellular scenarios. Because 13C MFA obtains signif-
icant ﬂux information from isotopomer abundance data, it is a
powerful method of estimating ﬂuxes independent of cofactors.
13C MFA revealed that almost all the galactose entering the cell
was metabolized via glycolysis with ∼10% of it passing through
the oxidative PPP (Figure 6). This is clear from the MIDs of the
fragment of alanine in the 100% 1-13C galactose labeling experi-
ment (Figures 5A,B and Data Sheet 2 in Supplementary Material).
The [123] fragment of pyruvate (and of alanine, which is derived
from it) is synthesized from the [321] and [456] fragments of
galactose. The oxidative PPP results in the loss of the C-1 carbon
of galactose. Thus, alanine synthesized from carbon that passed
through theoxidativePPP should exhibit a [123] fragmentwith the
MID {m+0: 100%; m+1: 0%; m+2: 0%; m+3: 0%}. Conversely,
alanine synthesized from carbon that passed through glycolysis
should exhibit a [123] fragment with the MID {m+0: 50%; m+1:
50%; m+2: 0%; m+3: 0%}. In our 100% 1-13C galactose labeling
experiment, we observed an MID of {m+0: 52%; m+1: 46%;
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FIGURE 4 | Characterization of engineered yeast strains Fy0, FyAA,
and FyDHA used in this study. (A) Gene expression assay of ADS,
CYP71AV1, CPR, FDS, DBR2, a negative control (A. annua actin1) and two
positive controls (ACT1 andTAF10). This assay was performed in duplicate
at multiple time points; only one replicate is shown. This assay showed
that as expected, strain FyAA expresses ADS, CYP71AV1, CPR, and FDS,
whereas strain FyDHA expresses these genes and DBR2. (B) Cell
growth curves (left axis) and DHA titer for FyDHA strain (right axis):
white circles, Fy0; gray circles, FyAA; black circles, FyDHA; black
triangles, DHA titer of FyDHA. (C)Yield calculations of ethanol (asterisks)
and glycerol (plus signs) on glucose and galactose for all three
strains.
m+2: 1%; m+3: 0%} for the alanine [123] fragment (Figure 5B),
indicating that the oxidative PPP was nearly inactive. Data from
other amino acid fragments in this experiment as well as the 20%
U-13C galactose labeling experiment also concur with this result.
Because the oxidative PPP generates two NADPH molecules for
every molecule of glucose-6-phosphate metabolized through it
and is featured in many DHA-synthesizing ExPas identiﬁed above,
amplifying ﬂux through it is a key metabolic engineering strat-
egy toward improving DHA yield. A possible candidate gene for
overexpression is glucose-6-phosphate dehydrogenase G6PDH2,
which is known to be the rate-limiting enzyme in this pathway in
S. cerevisiae (Kwon et al., 2006).
Furthermore, the isotopomer data revealed that the TCA
cycle carried lower ﬂux than expected under aerobic conditions
(Figures 5C,D). This is evident from the MIDs of the aspartic
acid fragment [1234] {m+0: 66%; m+1: 15%; m+2: 3%; m+3:
14%; m+4: 2%} and alanine fragment [123] {m+0: 78%; m+1:
3%; m+2: 1%; m+3: 18%}from the 20% U-13C galactose labeling
experiment (Figure 5D and Data Sheet 2 in Supplementary Mate-
rial). Assuming that the 13C enrichment of intracellular CO2 is
approximately the same as that of the supplied galactose, synthesis
of the fragment [1234] of the TCA cycle intermediate oxaloacetate,
and thereby of aspartic acid, purely through the anaplerotic reac-
tion pyruvate + CO2  oxaloacetate should result in the MID
{m+0: 64%; m+1: 16%; m+2: 0%; m+3: 16%; m+4: 4%} for the
aspartic acid [1234] fragment. Synthesis of oxaloacetate through
the TCA cycle itself should result in a very different MID because
of the carbon atom rearrangements in that pathway (Figure 5D).
The closeness of the aspartic acid [1234] fragment MID to that
predicted through pure anaplerotic synthesis indicates that the
TCA cycle has very little ﬂux relative to the anaplerotic reactions
or glycolysis (Figure 6).
COMPARISON OF 13C MFA AND ExPa FLUX DISTRIBUTIONS IDENTIFIES
FURTHER METABOLIC ENGINEERING TARGETS
The selection of a preferred DHA-producing ExPa from amongst
the 1000+ ExPas elucidated by us would depend on the ease
with which the FyDHA strain can be engineered to emulate the
ExPa. Therefore, as a step to identify gene targets for improved
DHA production, we compared the ﬂux distribution of strain
FyDHA and the desired DHA- and biomass-synthesizing ExPas
C and D from Figures 3C,D (Table 2). Because these ExPas
are optimal DHA- and biomass-producing modes, emulating
them should result in an improvement of overall DHA yield.
Gene overexpressions necessary for FyDHA to emulate ExPa C
include pyruvate dehydrogenase, ME2 and pyruvate carboxylase.
Genetic interventions necessary to emulate ExPa D include
overexpression of pyruvate dehydrogenase, glucose-6-phosphate
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FIGURE 5 | 13C labeling patterns of proteinogenic amino acids evince
negligible PPP flux and lowTCA cycle flux in all three yeast strains.
(A) Ala[23] fragment, (B) Ala[123] fragment, (C) Asp[12] fragment (D)
Asp[1234] fragment. The observed MIDs of the Ala fragments of all three
strains closely resembled MIDs simulated by assuming that all carbon is
processed by glycolysis (“pure glycolysis” bar), and were substantially
different from MIDs simulated by assuming that all carbon passed through
the PPP. This evidences negligible PPP ﬂux in all three strains. The observed
MIDs of both the Asp fragments more closely resembled simulated MIDs
corresponding to the synthesis of oxaloacetate through anaplerosis than
those corresponding to oxaloacetate synthesis through theTCA cycle. This
suggests lowTCA cycle ﬂux in all three strains.
dehydrogenase, transaldolase, and transketolase as well as knock-
down of glucose-6-phosphate isomerase (Table 2). Common
to both ExPas is pyruvate dehydrogenase, which catalyzes the
pyruvate  acetyl-CoA reaction. The rationale for overexpress-
ing it is that the DHA-synthesizing strain has a low ﬂux from
pyruvate to acetyl-CoA, which would limit the carbon available
for DHA production, as acetyl-CoA is the precursor for the
MVA pathway. A strong alternative to pyruvate dehydrogenase
would be acetyl-CoA synthetase, which plays a role in the pyru-
vate acetaldehyde acetate acetyl-CoAroute that is reported
to be amajor source of acetyl-CoA in S. cerevisiae (Hynes andMur-
ray, 2010). Another alternative may be ATP citrate lyase, which
produces acetyl-CoA from citrate. However, this pathway may not
be a major source of cytosolic acetyl-CoA in S. cerevisiae (Hynes
and Murray, 2010).
Other gene targets in Table 2 belong to two categories: one
involves improving ﬂux through the PPP (overexpression of
glucose-6-phosphate dehydrogenase, transketolase, transaldolase)
and reducing the glycolytic ﬂux (knockdown of glucose-6-
phosphate isomerase), whereas the other involves increasing
ﬂux through the malate  pyruvate reaction catalyzed by
ME2. Both of these are complementary approaches that look
to improve NADPH availability for DHA and biomass produc-
tion. It should be noted that there is a likelihood of some
ME2 ﬂux in the yeast strains of this study. In the model we
used for 13C MFA, all anaplerotic ﬂux was consolidated into a
single bidirectional reaction maef, because our isotopomer mea-
surements could not resolve the different possibilities for this
ﬂux: phosphoenolpyruvate carboxykinase, phosphoenolpyruvate
carboxylase, and pyruvate carboxylase (phosphoenolpyruvate or
pyruvate+CO2  oxaloacetate) as well as NADH-dependent and
NADPH-malic enzyme (pyruvate + CO2  malate). The ﬂux
distributions returned by 13C MFA included a low net ﬂux (0.02)
but substantial reversibility (0.97–0.98) for this consolidated
anaplerotic ﬂux, translating to forward (0.78) and reverse (0.76)
ﬂuxes that were signiﬁcant, yet an order of magnitude smaller than
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FIGURE 6 | Flux distributions obtained by 13C MFA for the three
engineered yeast strains. (A) Fy0; (B) FyAA; (C) FyDHA. All three strains
show similar ﬂux distributions with a substantial fraction of glucose carbon
shunted to ethanol and glycerol production. All strains exhibited large ﬂuxes
through glycolysis and negligible or low ﬂuxes through both the oxidative PPP
and theTCA cycle.
Table 2 | Genetic engineering targets determined by comparing ExPa analysis with 13C MFA.
ExPa C ExPa D
DHA yield 0.18 0.11
Biomass yield 0.03 0.06
NADPH supplied by ME2 PPP
Gene overexpression in strain
FyDHA necessary to emulate
this ExPa
1. YBR221C,YER178W,YFL018C,YGR193C,YNL071W
(pyruvate dehydrogenase)
2. YKL029C (NADPH-malic enzyme ME2)
3. YBR218C,YGL062W (pyruvate carboxylase)
1. YBR221C, YER178W, YFL018C, YGR193C, YNL071W
(pyruvate dehydrogenase)
2. YNL241C (glucose-6-phosphate dehydrogenase)
3. YGR043C,YLR354C (transaldolase in PPP)
4. YBR117C,YPR074C (transketolase in PPP)
Gene knockdown in strain FyDHA
necessary to emulate this ExPa
1.YBR145W,YGL256W,YOL086C (alcohol
dehydrogenase)
1.YBR145W,YGL256W,YOL086C (alcohol dehydrogenase)
2.YBR196C (glucose-6-phosphate isomerase)
The characteristics of two key ExPas with reasonable DHA and biomass yields are shown, with the corresponding genetic engineering targets to emulate these
ExPas in FyDHA. Common targets include eliminating ethanol biosynthesis by deleting alcohol dehydrogenase and increasing ﬂux from pyruvate to acetyl-CoA by
overexpressing pyruvate dehydrogenase.
the glycolytic ﬂux (∼5.0; Data Sheet 2 in Supplementary Mate-
rial and Figure 6). ME2 may contribute to this ﬂux, although
this contribution remains unresolved. However, a comparison
with ExPa B or C (Figures 3B,C) shows that even a 100% con-
tribution by ME2 to this ﬂux is insufﬁcient to meet NADPH
demand.
FBA AND MOMA ANALYSIS OF THE MODIFIED iMM904
GENOME-SCALE MODEL REVEAL MULTIPLE GENETIC INTERVENTION
STRATEGIES FOR IMPROVING DHA YIELDS
Fluxbalance analysis, a complementary approach to 13CMFA,esti-
mates or predicts ﬂuxes using linear programming techniques. It is
particularly useful for analysis of metabolism at the genome-scale.
MOMA is an extension of the FBA approach that identiﬁes non-
trivial gene knockouts toward optimizing a metabolic objective,
such as the yield of a product. Its use toward determining gene
targets has been reported in multiple successful studies (Alper
et al., 2005; Park et al., 2007; Asadollahi et al., 2009; Ranganathan
et al., 2012). We performed genome-scale FBA and MOMA analy-
sis by using a modiﬁed iMM904 model (Mo et al., 2009). First, we
used the ﬂuxes obtained from 13C MFA of the FyDHA strain for
constraining ﬂuxes in the iMM904 model, and then used FBA to
predict a ﬂux distribution for this strain. Then, we used MOMA
analysis to simulate ﬂuxes in single- and double-gene knockouts
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of the FyDHA strain to study the effects of these knockouts onDHA
yields.
We initially observed that even with double-gene knockouts,
DHA yields did not improve signiﬁcantly over those of FyDHA.
This is because MOMA minimizes ﬂux changes between the
knocked out and control strains, and the low ﬂuxes of NADPH-
supplying reactions in the FyDHA strain prevented MOMA from
identifying knockouts for improving DHA yield. Consequently,
we modiﬁed the ﬂux distribution of FyDHA in silico such that it
had equal ﬂuxes through PPP and glycolysis, but its DHA yield
was the same as the measured yield of FyDHA. We performed
subsequent MOMA analysis on this new baseline strain FyDHA’.
Subsequent MOMA analysis found 401 single-gene knockouts
with signiﬁcantly increased DHA ﬂux compared to FyDHA’. We
then used the single-gene knockouts associated with the high-
est DHA yields to identify double-gene knockouts that would
potentially exhibit even higher DHA yields. The MOMA analysis
predicted substantially improved DHA yields in these knockouts
(Data Sheet 3 in Supplementary Material). In many cases, the
increase in DHA yield was accompanied by an expected decrease
in biomass yield, because knocking out genes can lead to subopti-
mal growth as the products of the knocked out genes are no longer
available for biomass synthesis. A good gene knockout strategy
should improve DHA yields substantially with a modest decrease
in biomass growth rate.
The best double-gene knockout strategy predicted by MOMA
includes the genes YKL120W and YKL106W, and improves DHA
yield to 4.2 mol % (70-fold over the baseline), while reducing
biomass yield by only 2.2-fold compared to FyDHA’. Figure 7
presents an interpretation of this strategy. First, FBA predicted
that FyDHA’ loses a signiﬁcant amount of mitochondrial acetyl-
CoA toCO2 through a cyclic, cytosolic pathway that containsmost
steps of the TCA cycle. Both YKL120W and YKL106W code for
enzymes or transporter proteins in facilitating this cycle.YKL120W
or OAC1 codes for an oxaloacetate transporter catalyzing the
transport oxaloacetate[c] + H+[c]  oxaloacetate[m] + H+[m],
where [c] and [m] denote the cytosol and mitochondrion, respec-
tively. YKL106W or AAT1 codes for an aspartate aminotransferase
catalyzing the reaction α-ketoglutarate[m] + L-aspartate[m]  L-
glutamate[m] + oxaloacetate[m]. Thus, knocking out YKL120W
and YKL106W breaks this cycle while not affecting biomass pro-
duction, allowing mitochondrial acetyl-CoA to be diverted toward
downstream pathways including DHA biosynthesis. Of these two
genes, YKL120W has a greater effect on reducing ﬂux toward
FIGURE 7 | MOMA analysis identifies double-gene knockouts in primary
metabolism that funnel carbon toward DHA. As per one MOMA
prediction, engineering the FyDHA strain by knocking out two genes (1: OAC1
orYKL120W, which codes for an oxaloacetate transporter and 2: AAT1 or
YKL106W, which codes for an aspartate aminotransferase) should result in
4.2 mol DHA per 100 mol of glucose, which amounts to a ∼70-fold increase
as compared to our current yield and translates to ∼18% of the theoretical
yield of DHA from glucose. This metabolic map depicts the mechanism by
which these two deletions accomplish the ﬂux redirection. Red arrows
indicate decreased ﬂux and green arrows indicate increase in ﬂux relative to
our (control) DHA-producing strain; arrow thicknesses and numbers
alongside the arrows represent ﬂux differences between the baseline
strain FyDHA’ and the double-gene knockout strain are in arbitrary units.
On the basis of the 13C isotopomer results, FBA predicted that our control
strain loses a signiﬁcant amount of mitochondrial acetyl-CoA (ACoAm)
to CO2 through a cyclic, cytosolic pathway that contains most steps of
theTCA cycle. Knocking outYKL120W andYKL106W breaks this cycle
while not signiﬁcantly affecting biomass production, thus allowing ACoAm
to be diverted toward downstream pathways including DHA
biosynthesis.
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mitochondrial oxaloacetate, and also shows up as part of the next
best double-gene knockout pair for improving DHA yield (Data
Sheet 3 in Supplementary Material).
A limitation of using FBA-type methodologies to predict
genetic engineering strategies is their reliance of the assumption
of optimized metabolism to predict ﬂux distributions. However,
engineered strains may perform sub-optimally. Thus, while FBA
is valuable in identifying non-trivial gene targets, it is ambitious
to expect the real engineered strain to exhibit yields close to the
FBA-predicted yields. Additionally, a recent statistical analysis of
previous studies on the production of chemicals by engineered
S. cerevisiae found that genetic intervention improved product
yield only by two- to fourfold in a majority of the 40 studies
examined, and that chemicals requiring multiple enzymatic steps
were associated with lower yields (Varman et al., 2011). Along the
same lines, implementation of the best gene knockout strategy
suggested by our study may result in a DHA yield improvement
tangibly lower than the predicted 70-fold increase. Very likely, one
round of genetic engineering in accordance with FBA predictions
may necessitate further rounds of engineering to overcome further
bottlenecks to product yield.
CONCLUSION
In summary, we investigated various in silico and in vivo
approaches – ExPa analysis, 13C MFA, FBA, and MOMA analy-
sis – to identify metabolic engineering strategies for improving
DHA yield in an engineered yeast strain. Our analyses revealed
three major metabolic engineering strategies toward this objec-
tive. The ﬁrst, most obvious strategy is reduction of ﬂux from
pyruvate to ethanol and directing this ﬂux toward acetyl-CoA
by knocking out fermentative pathways and overexpressing pyru-
vate dehydrogenase. However, in the absence of further genetic
intervention, the available carbon is not likely to be redirected
toward the desired pathway. A thorough investigation of the sys-
tem using detailed 13C MFA, and FBA and MOMA analysis was
required to decipher further non-intuitive strategies. A second
strategy toward higher DHA yield is the improvement of NADPH
availability by overexpressing ME2 or a rate-limiting step of the
oxidative PPP such as G6PDH2. Harnessing the oxidative PPP
for NADPH supply suffers from the disadvantage that a sixth
of the carbon entering this pathway is lost as CO2; hence, this
lowers the yield of DHA signiﬁcantly. A third strategy is push-
ing ﬂux from mitochondrial acetyl-CoA toward DHA production.
These two strategies are necessary for overcoming the NADPH
and mitochondrial acetyl-CoA availability bottlenecks en route to
DHA biosynthesis. We anticipate that comprehensive analysis of a
similar type can be applied to any metabolic system to reveal intu-
itive and non-intuitive genetic engineering targets for optimizing
the production of a target molecule. Such systemic analysis is an
important step toward realizing the goal of rational metabolic
engineering.
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